Flagship Biosciences Acquires Interpace Pharma Solutions from Interpace Biosciences
September 1, 2022
Flagship Biosciences has acquired Interpace Pharma Solutions (IPS), a division of Interpace Biosciences, expanding Flagship's molecular pathology, cytogenetics, genomics and biomarker analytics capabilities. The deal follows a growth equity investment in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies and adds a state-of-the-art laboratory in Research Triangle Park, North Carolina to Flagship's service offering.
- Buyers
- Flagship Biosciences, Inc., Ampersand Capital Partners, BroadOak Capital Partners, Research Corporation Technologies
- Targets
- Interpace Pharma Solutions (IPS)
- Sellers
- Interpace Biosciences
- Industry
- Healthcare Services
- Location
- North Carolina, United States
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.